Immucell (ICCC) Capital Expenditures (2010 - 2025)
Immucell's (ICCC) quarterly Capital Expenditures came in at -$1.1 million in Q4 2025, down 304.94% YoY from $523785.8 in Q4 2024, and down 280.74% on a QoQ basis from $593924.0 in Q3 2025.
Immucell (ICCC) Capital Expenditures (2010 - 2025) Analysis & Trends
Immucell (ICCC) has 16 years of Capital Expenditures data on file, last reported at -$1.1 million in Q4 2025.
- Quarterly Capital Expenditures fell 304.94% year-over-year to -$1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4685.0 (up 5.97% YoY) and the FY2025 annual result came in at $4685.0, up 5.97% from the prior year.
- Capital Expenditures slipped to -$1.1 million in Q4 2025, from $593924.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.5 million in Q4 2022 to a low of -$1.1 million in Q4 2025.
- A 5-year average of $424277.1 and a median of $507219.5 in 2023 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2024 — Capital Expenditures plunged 425.89% — and 2025, when it surged 571.77%.
- Tracing ICCC's Capital Expenditures over 5 years: stood at $704594.0 in 2021, then jumped by 111.49% to $1.5 million in 2022, then slumped by 94.54% to $81344.0 in 2023, then sank by 425.89% to -$265088.0 in 2024, then sank by 304.94% to -$1.1 million in 2025.
- The last three Capital Expenditures figures came in at -$1.1 million (Q4 2025), $593924.0 (Q3 2025), and $155159.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.93 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.59 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.86 Bn | 53.73 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.42 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.19 Bn | 9.80 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 251.02 Mn |
| 10 | Immucell | 91.10 Mn | 82.24 Mn | 2.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.07 Mn |
| Dec 31, 2025 | -1.07 Mn |
| Sep 30, 2025 | 593,924.00 |
| Sep 30, 2025 | 593,924.00 |
| Jun 30, 2025 | 155,159.00 |
| Jun 30, 2025 | 155,159.00 |
| Mar 31, 2025 | 329,050.00 |
| Mar 31, 2025 | 329,050.00 |
| Dec 31, 2024 | -265,088.00 |
| Dec 31, 2024 | -265,088.00 |
| Sep 30, 2024 | 88,412.00 |
| Sep 30, 2024 | 88,412.00 |
| Jun 30, 2024 | 110,741.00 |
| Jun 30, 2024 | 110,741.00 |
| Mar 31, 2024 | 70,356.00 |
| Mar 31, 2024 | 70,356.00 |
| Dec 31, 2023 | 81,344.00 |
| Dec 31, 2023 | 81,344.00 |
| Sep 30, 2023 | 420,515.00 |
| Sep 30, 2023 | 420,515.00 |